The sensitivity and specificity of fundus autofluorescence and the correlations of fundus autofluorescence and spectral domain optical coherence tomography in polypoidal choroidal vasculopathy

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

TCTR

Registry ID

TCTR20161018001

Enrollment

150

Registered

2016-10-18

Start date

2015-07-01

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

polypoidal choroidal vasculopathy and choroidal neovascularization PCV CNV FAF

Interventions

patients with polypoidal choroidal vasculopathy,Type l and ll choroidal neovascularization of AMD

Diagnostic,Diagnostic

polypoidal choroidal vasculopathy,Neovascular age related macular degeneration

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: -patients with serous/hemorrhagic pigment epithelial detachments (PEDs) and indocyanine green angiography (ICGA) diagnosed as Polypoidal choriodal vasculopathy (PCV) or neovascular age-related macular degeneration -Patients have Spectal domain optical coherence tomography (SD-OCT) before treatment -Fundus autofluorescence (FAF) available at the same visit of SD-OCT

Exclusion criteria

Exclusion criteria: -no prior treatment that altered the clinical findings eg. focal laser -No SD-OCT and FAF available together with ICGA -complex findings of fundus signs - -patients with massive subretinal or subretinal pigement epithelial hemorrhage) -Scar formation

Design outcomes

Primary

Measure	Time frame
Fundus autofluorescence 1 years sensitivity, specificity	—

Secondary

Measure	Time frame
Optical coherence tomography 1 years percentage	—

Countries

Thailand

Contacts

Public ContactSupalert Prakhunhungsit

Faculty of Medicine Siriraj hospital

off_sp25@hotmail.com024198033

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026